Overview
Matching Treatment to Mutations: Clinical Pathways to Optimize RET+ Testing in NSCLC and Thyroid Cancer
Click the "View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Precision medicine continues to rapidly evolve in cancer care, and expert perspectives on recent advances can help you improve patient outcomes. This recording from a series of expert-led small group meet-ups will increase your knowledge of RET inhibitors, lead to greater confidence in utilizing biomarkers to inform your treatment decisions, and improve collaboration between oncologists and pathologists to optimize precision medicine for RET-positive metastatic NSCLC and advanced thyroid cancer.
This activity also reviews patient cases that incorporate the latest clinical evidence and recommendations and includes excerpts from live discussion sessions as well as downloadable slides to improve care for your patients with NSCLC and thyroid cancer.
This activity is intended for oncologists and pathologists who care for/manage patients with NSCLC and thyroid cancer.
With over 55% of cancer patients treated by community oncologists, it’s imperative that community oncologists and pathologists apply a dual/multidisciplinary team approach to caring for cancer patients. As precision medicine continues to evolve in cancer care, integration of pathologists within clinical care pathways to interpret test results and offer recommendations for biomarker testing aid in personalized treatment approaches.
Upon completion of the educational activity, participants should be able to:
• Introduce improved models for early and effective biomarker testing
• Identify appropriate patients and optimize treatment for RET targeted therapy
• Develop strategies to mitigate challenges and barriers to optimizing RET testing for patients with NSCLC and thyroid cancer
• Introduce improved models for early and effective biomarker testing
• Identify appropriate patients and optimize treatment for RET targeted therapy
• Develop strategies to mitigate challenges and barriers to optimizing RET testing for patients with NSCLC and thyroid cancer
Sponsored by the Academy for Continued Healthcare Learning (ACHL) and Penn State College of Medicine.
This activity is supported by an educational grants from Lilly and Genentech, Inc.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to (1) continuing certification point in the American Board of Pathology’s Continuing Certification program. This activity offers the following type of credit: Lifelong Learning (Part II).
Penn State College of Medicine requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
Marcia Brose, MD, PhD, FASCO
Director, Cancer Services
Vice Chair, Hematology and Medical Oncology
Co-Director Community Based Clinical Trials
Sidney Kimmel Cancer Center - Jefferson Health
Philadelphia, PA
Director, Cancer Services
Vice Chair, Hematology and Medical Oncology
Co-Director Community Based Clinical Trials
Sidney Kimmel Cancer Center - Jefferson Health
Philadelphia, PA
Justin Gainor, MD
Associate Professor of Medicine at Harvard Medical School
Director, Center for Thoracic Cancers
Director of Targeted Immunotherapy
Massachusetts General Hospital
Boston, MA
The following financial relationships have been provided:
Marcia Browse, MD, PhD, FASCO
Consultant: Bayer, Blueprint Medicines, Eisai Co., Ltd., Exelixis, Inc., Lilly, Loxo Oncology/Lilly
Research Support: Bayer, Blueprint Medicines, Eisai Co., Ltd., Exelixis, Inc., Lilly, Loxo Oncology/Lilly
Marcia Browse, MD, PhD, FASCO
Consultant: Bayer, Blueprint Medicines, Eisai Co., Ltd., Exelixis, Inc., Lilly, Loxo Oncology/Lilly
Research Support: Bayer, Blueprint Medicines, Eisai Co., Ltd., Exelixis, Inc., Lilly, Loxo Oncology/Lilly
Justin Gainor, MD
Compensated consultant and/or received honoraria: Bristol-Myers Squibb, Genentech, Ariad/Takeda, Loxo/Lilly, Blueprint, Oncorus, Regeneron, Gilead, Moderna, AstraZeneca, Pfizer, Novartis, Merck, and GlydeBio
Research support: Novartis, Genentech/Roche, and Ariad/Takeda
Institutional research support: Bristol-Myers Squibb, Tesaro, Moderna, Blueprint, Jounce, Array Biopharma, Merck, Adaptimmune, Novartis, and Alexo; and has an immediate family member who is an employee with equity at Ironwood Pharmaceuticals
ACHL, Penn State College of Medicine staff, and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 45-minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Questions regarding accreditation can be directed to ContinuingEd@pennstatehealth.psu.edu or 717-531-6483. Refer to course number G6771A–22-T.
Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring material activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
There is no fee to participate in this activity nor to generate certificates.
